Prostate Cancer Awareness | KTAR News

The American Cancer Society estimates that in the year 2017, 161,360 men will develop prostate cancer and 26,730 men will die from the disease, suggesting that Prostate cancer is the most common cancer in men. It is the third leading cause of death from cancer in men. Prostate cancer screening and more effective treatments have improved the 5 year survival rates, increasing from 66% in 1975 to 99% in 2005. Despite such dramatic improvements, PSA screening has remained controversial.

There have been legitimate concerns about false positive PSA’s prompting unnecessary prostate biopsies, the overdiagnosis and overtreatment of men who were not going to die from their disease, and the main complications associated with prostate cancer treatment — Erectile Dysfunction and Urinary Incontinence (leakage). Despite these concerns, most urologists are in favor of screening, and they are using “Active Surveillance” (AS) for low-risk patients in order to offset the risk of overtreatment; however, they are generally failing to properly address the complications of Erectile Dysfunction (ED) and Urinary Incontinence (UI). 

Read the full article at

You Might Also Enjoy...

Erectile Dysfunction and the Cardiovascular Disease Connection

Erectile Dysfunction (ED) is defined by the National Institutes of Health as the inability of a man to achieve and maintain a penile erection sufficient for sexual activity.  ED is extremely prevalent, affecting up to 30 million men in the United States...

New Frontiers with Testosterone Replacement Therapy

Over the last 2 decades, there has been growing awareness of the impact of testosterone deficiency (TD) on men’s health. This includes body composition (reduced muscle mass and increased body fat), bone density, mood, and quality of life.

Is Testosterone Treatment Good for the Prostate?

Despite the well-proven benefits for testosterone replacement therapy (TRT), physicians are still fearful that testosterone may cause the progression of undiagnosed prostate cancer (PCa) or its development with advancing age.